ENZN Enzon Pharmaceuticals Inc

Price (delayed)

$0.5496

Market cap

$40.79M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.04

Enterprise value

-$7.4M

Highlights
ENZN's revenue has surged by 66% year-on-year
The gross profit has soared by 66% YoY
Enzon Pharmaceuticals's net income has decreased by 24% YoY but it has increased by 19% QoQ
The equity has grown by 18% YoY but it has contracted by 7% from the previous quarter
The company's EPS has shrunk by 100% YoY and by 33% QoQ
ENZN's quick ratio is down by 11% since the previous quarter

Key stats

What are the main financial stats of ENZN
Market
Shares outstanding
74.21M
Market cap
$40.79M
Enterprise value
-$7.4M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.94
Price to sales (P/S)
94.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-17.17
Earnings
Revenue
$431,000
EBIT
-$1.05M
EBITDA
-$1.05M
Free cash flow
-$33,000
Per share
EPS
-$0.04
Free cash flow per share
$0
Book value per share
$0.09
Revenue per share
$0.01
TBVPS
$0.65
Balance sheet
Total assets
$48.29M
Total liabilities
$41.43M
Debt
$0
Equity
$6.87M
Working capital
$47.83M
Liquidity
Debt to equity
0
Current ratio
104.75
Quick ratio
104.53
Net debt/EBITDA
45.85
Margins
EBITDA margin
-243.9%
Gross margin
100%
Net margin
-245.5%
Operating margin
-244.5%
Efficiency
Return on assets
-7.5%
Return on equity
-32.4%
Return on invested capital
N/A
Return on capital employed
-2.2%
Return on sales
-243.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENZN stock price

How has the Enzon Pharmaceuticals stock price performed over time
Intraday
-8.35%
1 week
-9.4%
1 month
-15.45%
1 year
221.03%
YTD
121.26%
QTD
-16.73%

Financial performance

How have Enzon Pharmaceuticals's revenue and profit performed over time
Revenue
$431,000
Gross profit
$431,000
Operating income
-$1.05M
Net income
-$1.06M
Gross margin
100%
Net margin
-245.5%
ENZN's net margin has surged by 90% since the previous quarter and by 25% year-on-year
ENZN's operating margin has soared by 90% from the previous quarter and by 25% YoY
ENZN's revenue has surged by 66% year-on-year
The gross profit has soared by 66% YoY

Growth

What is Enzon Pharmaceuticals's growth rate over time

Valuation

What is Enzon Pharmaceuticals stock price valuation
P/E
N/A
P/B
5.94
P/S
94.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-17.17
The company's EPS has shrunk by 100% YoY and by 33% QoQ
The stock's price to book (P/B) is 80% more than its last 4 quarters average of 3.3
The equity has grown by 18% YoY but it has contracted by 7% from the previous quarter
The P/S is 122% above the 5-year quarterly average of 42.6 but 40% below the last 4 quarters average of 156.8
ENZN's revenue has surged by 66% year-on-year

Efficiency

How efficient is Enzon Pharmaceuticals business performance
Enzon Pharmaceuticals's return on equity has shrunk by 187% YoY and by 9% QoQ
The company's return on sales has surged by 90% QoQ and by 25% YoY
ENZN's return on assets is up by 30% since the previous quarter and by 18% year-on-year

Dividends

What is ENZN's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Enzon Pharmaceuticals financials performed over time
Enzon Pharmaceuticals's total assets is 17% more than its total liabilities
The current ratio has decreased by 11% from the previous quarter
ENZN's quick ratio is down by 11% since the previous quarter
ENZN's debt is 100% smaller than its equity
The equity has grown by 18% YoY but it has contracted by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.